EUCODIS presented latest developments of CTATTM, its proprietary ADC linker technology at the10th Annual Protein Engineering Summit (PEGS) in Boston, May 5th – 9th.
CTATTM is a novel, enzyme-based technology for the directed c-terminal conjugation of antibodies with a broad spectrum of different payload molecules. In contrast to existing first generation chemical linker technologies or second generation site-specific linker technologies, the CTATTM technology combines the benefits of efficient c-terminal, site-directed conjugation without affecting the specificity and stability of the antibody.
EUCODIS Bioscience and BiAqua, an innovative start-up company designing biotechnology based solutions for water treatment, announced today the successful production of the first industrial pilot batch of Pyrococcus furiosus ferritin for application in biofouling treatment.
Biofouling is recognized in the industry as being one of the key issues in the multi-billion market for reverse osmosis membranes. BiAqua’s technology is unique in that it uses enzymes for the selective and near complete removal of phosphate from water, which largely prevents the growth of bacteria and translates into direct and indirect benefits for operation of desalination equipments.
EUCODIS Bioscience is pleased to announce the attainment of an ISO9001 certified Quality Management System.
Ursula Baumgartner-Durchschlag, Quality Manager, adds: “In compliance with the ISO9001 standard we commit ourselves to high quality standards at all levels from R&D to manufacturing and quality control. This guarantees highly reliable services and products to all our customers.”